Clinical Trials Browser

Unknown × pembrolizumab × Lymphoid × Clear all

NCT03789097 2024-01-30

Vaccination With Flt3L, Radiation, and Poly-ICLC

Phase 1/2 Unknown

BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT05296772 2023-09-06

Phase 1 First-in-human Study of JS014

Phase 1 Unknown

Lymphoma, Neoplasms, Neoplasms, Experimental

NCT03331731 2023-08-21

PLIMATH

Phase 2 Unknown

Hodgkin Disease

NCT03077828 2023-06-02

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Unknown

43 enrolled 9 charts

Hodgkin Disease

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03021057 2019-04-17

Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas

Phase 2 Unknown

Lymphoma, T-Cell

NCT03107962 2017-04-11

Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell